Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Foncology%2Fsabcs-2021%2Fneratinib-plus-trastuzumab-plus-fulvestrant-shows-encouraging-clinical-activity%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Conference+Report+Article%7CTriple-Negative+Breast+Cancer%7CBreast+Cancer%7CSABCS+2021%7COncology&conference=SABCS+2021): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity - Medical Conferences

Home > Oncology > SABCS 2021 > Triple-Negative Breast Cancer > Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity

Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity

Presented By
Dr Komal Jhaveri, Memorial Sloan Kettering Cancer Center, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 2, SUMMIT

Both patients with heavily pretreated hormone receptor (HR)-positive/HER2-mutated, HER2-negative metastatic breast cancer and patients with heavily pretreated HER2-mutated metastatic triple-negative breast cancer (TNBC) have encouraging responses to treatment with neratinib plus trastuzumab plus fulvestrant.

HER2 mutation in the absence of gene amplification or protein overexpression is a unique mechanism of oncogenetic addiction to HER2 signalling [1]. Neratinib has demonstrated encouraging clinical activity either as a single agent or in combination with fulvestrant in HER2-mutated, HER2-non-amplified metastatic breast cancer [2]. Addition of trastuzumab to neratinib plus fulvestrant showed encouraging clinical activity with durable responses in the phase 2 SUMMIT trial (NCT01953926). Early data also suggest that neratinib plus fulvestrant plus trastuzumab improves clinical benefit in patients with HER2-mutated, HER2-non-amplified metastatic breast cancer [3].

Based on these findings, SUMMIT has recently been expanded to include a randomised comparison of neratinib plus fulvestrant plus trastuzumab (‘triplet’) versus fulvestrant plus trastuzumab (‘doublet’) versus fulvestrant alone (‘mono’) in 21 patients with HR-positive/HER2-mutated, HER2-negative metastatic breast cancer who were exposed to CDK4/6 inhibitors. Prior to starting this randomised portion of the trial, 26 patients were already enrolled in a non-randomised cohort receiving neratinib plus fulvestrant plus trastuzumab. In another SUMMIT cohort, 18 patients with HER2-mutant TNBC were enrolled in a non-randomised cohort and received neratinib plus trastuzumab. Dr Komal Jhaveri (Memorial Sloan Kettering Cancer Center, NY, USA) presented the results [4].

In the non-randomised, triplet-treated patients (n=26) objective response rate was 46.2% (all partial response), clinical benefit rate was 57.7%, and median progression-free survival was 8.2 months. In the randomised, triplet-treated patients (n=7) objective response rate was 28.6% (14.3% complete response, 14.3% partial response), clinical benefit rate was 28.6%, and median progression-free survival was 6.2 months. No responses were seen in de doublet-treated and mono-treated patients.

These results are in line with the hypothesis that neratinib is critical for the inhibition of HER2 mutations. Based on these results the doublet-cohort and mono-cohort were closed. In the combined randomised and non-randomised triplet cohort (n=33) objective response rate was 42.4% (3% complete response, 39.4% partial response), clinical benefit rate was 51.5%, and median progression-free survival was 7.0 months. In the TNBC cohort (n=18) objective response rate was 33.3% (5.6% complete response, 27.8% partial response), clinical benefit rate was 38.9%, and median progression-free survival was 6.2 months (see Table).

Table: Baseline characteristics and efficacy of TNBC patients treated with neratinib plus trastuzumab [4].



 

 

 

 

 

 

 

 

CR, confirmed response; PR, partial response; CI, confidence interval; DOR, duration of response; NE, not estimable; PFS, progression-free survival

Based on these result, Dr Jhaveri concluded that “the combination regimen of neratinib plus fulvestrant plus trastuzumab demonstrates encouraging clinical activity in patients with heavily pretreated HR-positive/HER2-mutated, HER2-negative metastatic breast cancer who had previously received CDK4/6 inhibitors.”

  1. Nayar U, et al. Nat Genet 2019;51:207–216.

  2. Smyth LM, et al. Cancer Discov 2020;10:198–213.

  3. Jhaveri K, et al. PD1-05, SABCS 2020 Virtual Symposium, 8–11 December.

  4. Jhaveri K, et al. Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. GS4-10, SABCS 2021 Virtual Meeting, 7–10 December.

Copyright ©2022 Medicom Medical Publishers



Posted on